CA3185849A1 - Compounds and methods for the treatment of eye disorders - Google Patents
Compounds and methods for the treatment of eye disordersInfo
- Publication number
- CA3185849A1 CA3185849A1 CA3185849A CA3185849A CA3185849A1 CA 3185849 A1 CA3185849 A1 CA 3185849A1 CA 3185849 A CA3185849 A CA 3185849A CA 3185849 A CA3185849 A CA 3185849A CA 3185849 A1 CA3185849 A1 CA 3185849A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901858A AU2020901858A0 (en) | 2020-06-05 | Compounds and Methods for the Treatment of Eye Disorders | |
| AU2020901856 | 2020-06-05 | ||
| AU2020901858 | 2020-06-05 | ||
| AU2020901856A AU2020901856A0 (en) | 2020-06-05 | Compounds and Methods for the Treatment of Eye Disorders | |
| PCT/US2021/035749 WO2021247900A1 (en) | 2020-06-05 | 2021-06-03 | Compounds and methods for the treatment of eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3185849A1 true CA3185849A1 (en) | 2021-12-09 |
Family
ID=78829970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3185849A Pending CA3185849A1 (en) | 2020-06-05 | 2021-06-03 | Compounds and methods for the treatment of eye disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230270703A1 (https=) |
| EP (1) | EP4161527A4 (https=) |
| JP (1) | JP2023529845A (https=) |
| KR (1) | KR20230024331A (https=) |
| CN (1) | CN116033901A (https=) |
| AU (1) | AU2021284380A1 (https=) |
| BR (1) | BR112022024728A2 (https=) |
| CA (1) | CA3185849A1 (https=) |
| IL (1) | IL298733A (https=) |
| MX (1) | MX2022015327A (https=) |
| WO (2) | WO2021247900A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023018314A2 (pt) * | 2021-03-17 | 2023-10-31 | Occurx Pty Ltd | Compostos para o tratamento de distúrbios e sais e polimorfos dos mesmos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6339814A (ja) * | 1986-08-01 | 1988-02-20 | Teisan Seiyaku Kk | トラニラストの経口用持続性製剤 |
| KR19990082523A (ko) * | 1996-02-15 | 1999-11-25 | 간자와 무츠와 | 혈관생성 억제제 |
| JPH09278653A (ja) * | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | 網膜疾患治療剤 |
| CN1252718A (zh) * | 1997-04-18 | 2000-05-10 | 橘生药品工业株式会社 | 预防或治疗与视网膜色素上皮细胞过度增殖相关的疾病的药剂 |
| ATE526041T1 (de) * | 2001-12-11 | 2011-10-15 | Fibrogen Inc | Verfahren zur hemmung okularer vorgänge |
| NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| JP2011006406A (ja) * | 2009-05-29 | 2011-01-13 | Santen Pharmaceut Co Ltd | トラニラストを含有する網膜疾患の予防または治療剤 |
| NZ609144A (en) * | 2010-11-24 | 2014-08-29 | Occurx Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
| US10780070B2 (en) * | 2013-10-18 | 2020-09-22 | The Schepens Eye Research Institute, Inc. | Alpha-aminoadipate for treatment of vision loss and restoring sight |
-
2021
- 2021-06-03 EP EP21818477.8A patent/EP4161527A4/en active Pending
- 2021-06-03 AU AU2021284380A patent/AU2021284380A1/en active Pending
- 2021-06-03 JP JP2022574480A patent/JP2023529845A/ja active Pending
- 2021-06-03 CN CN202180056862.4A patent/CN116033901A/zh active Pending
- 2021-06-03 MX MX2022015327A patent/MX2022015327A/es unknown
- 2021-06-03 CA CA3185849A patent/CA3185849A1/en active Pending
- 2021-06-03 KR KR1020237000380A patent/KR20230024331A/ko not_active Withdrawn
- 2021-06-03 BR BR112022024728A patent/BR112022024728A2/pt unknown
- 2021-06-03 US US18/007,714 patent/US20230270703A1/en active Pending
- 2021-06-03 IL IL298733A patent/IL298733A/en unknown
- 2021-06-03 WO PCT/US2021/035749 patent/WO2021247900A1/en not_active Ceased
- 2021-06-03 WO PCT/US2021/035750 patent/WO2021247901A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021284380A1 (en) | 2023-01-19 |
| EP4161527A4 (en) | 2024-06-26 |
| US20230270703A1 (en) | 2023-08-31 |
| KR20230024331A (ko) | 2023-02-20 |
| JP2023529845A (ja) | 2023-07-12 |
| IL298733A (en) | 2023-02-01 |
| MX2022015327A (es) | 2023-02-22 |
| WO2021247900A1 (en) | 2021-12-09 |
| BR112022024728A2 (pt) | 2023-03-07 |
| WO2021247901A1 (en) | 2021-12-09 |
| CN116033901A (zh) | 2023-04-28 |
| EP4161527A1 (en) | 2023-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8309612B2 (en) | Method for treating age-related macular degeneration | |
| CN100341506C (zh) | 含有阿斯匹林的药用组合物 | |
| RU2477132C2 (ru) | Применение четвертичных соединений пиридиния для вазопротекции и/или гепатопротекции | |
| RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
| CA3185849A1 (en) | Compounds and methods for the treatment of eye disorders | |
| CN113453677A (zh) | 用于治疗急性心房颤动的舒卡定施用 | |
| CN101015556B (zh) | 窦房结If电流抑制剂与钙抑制剂的组合以及含有它的药物组合物 | |
| WO2011149012A1 (ja) | イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用 | |
| KR20160113720A (ko) | 황 함유 모이어티를 포함하는 당 유도체 및 이의 제조 방법 및 mps iiic의 치료를 위한 이의 사용 방법 | |
| JP2023501967A (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| JP2004244409A (ja) | 糖尿病の発症予防薬 | |
| AU778148B2 (en) | 2-aminotetralin derivatives for the therapy of glaucoma | |
| CN113260612B (zh) | 用于治疗或预防肌营养不良症的化合物及其在医药用途中的治疗、改善或预防用衍生物 | |
| KR20210141203A (ko) | 에르도스테인 유도체 및 이를 함유하는 약학 조성물 | |
| US20110224200A1 (en) | Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde 0-(piperidin-1-yl-propyl)-oxime derivative as active ingredient | |
| US9579309B2 (en) | Prophylactic or therapeutic agent for posterior ocular disease containing tetrahydropyranylaminocyclopentylcarbonyltetrahydropyridopyridine derivative as effective ingredient | |
| EP2119440A1 (en) | Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease | |
| HK40049529A (en) | Compounds for treatment or prevention of muscular dystrophy and derivatives for treatment, amelioration or prevention in medical use thereof | |
| JPWO2010047369A1 (ja) | 糖尿病性腎症の治療剤 | |
| CN115557898A (zh) | 一种咪唑类化合物、其中间体及应用 | |
| HK40061591A (en) | Sulcardine administration for treatment of acute atrial fibrillation | |
| JP2009079041A (ja) | リチウム塩を有効成分として含有する後眼部疾患の治療又は予防剤 | |
| JPH10101563A (ja) | 抗酸化剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250504 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250505 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250606 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250609 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250818 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250818 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250818 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250818 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250818 |